Objectives: To study the effect of hepcidin on the course of chronic heart failure with anemia. Methods: 115 patients with CHF caused by ischemic heart disease (IHD) were chosen. All of them were treated in in-patient conditions and were followed in out-patient conditions. The patients were divided into two main and one control groups. Main group A consisted of 40 CHF patients with iron deficiency anemia. Main group B consisted of 35 CHF patients with anemia of chronic disease. 40 CHF patients without anemia were chosen for the control group. To patients of the main groups 200mg of Iron (III) hydroxide (Venofer®) was administered intravenously once in two days, along with standard CHF treatment. Results: Our study found reliable increase of serum levels hepcidin in CHF patients with anemia of chronic disease compared to CHF patients with iron deficiency anemia (45,4%) and control group (33%) (P<0,001). This, in turn, shows that hepcidin is an important indicator in differential diagnosis between anemia of chronic disease and iron deficiency anemia. Statistical analysis of pro-inflammatory cytokines and hepcidin levels was done in order to find any associations in patients of our study. Following was found: in group B weak positive correlation between hepcidin and IL-1 (r=0,24 Р<0,05), strong positive correlation between hepcidin and IL-6 (r=0,52, Р<0,001), and moderate positive correlation between hepcidin and TNF-α (r=0,37, Р<0,05). Conclusion: In CHF patients with anemia of chronic disease (Group B) hepcidin levels were reliably higher than normal ranges and correlation between pro-inflammatory cytokines and hepcidin during deterioration of the disease.
1. Akimova A.V., Nevskaya A.V., Milashchenko A.I., Kondrashova E.V. Osobennosti anemii khronicheskikh zabolevanii v terapevticheskom statsionare. Vestn. ural. med. akad. nauki. 2018; 15(1): 5–11. (in Russian) 2. Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20:125 –33. 3. Buratti P., Gammella E., Rybinska I., Cairo G., Recalcati S. Recent advances in iron metabolism: relevance for health, exercise, and performance. Med. Sci. Sports Exerc. 2015;47(8):1596–1604. [PubMed] 4. Caughey M.C., Avery C.L., Ni H., Solomon S.D., Matsushita K., Wruck L.M. et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am. J. Cardiol. 2014; 114(12): 1850–4. DOI: 10.1016/j. amjcard.2014.09.024. 5. Drozd M, Jankowska EA, Banasiak W,Ponikowski P. Iron therapy in patients with heart failure and iron de fi ciency: review of iron preparations for practitioners. Am J Cardiovasc Drugs 2017;17:183–201 . 6. Ebner N, Jankowska EA, Ponikowski P, et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol 2016;205:6 –12. 7. Elmuradov F.Kh., Razikov A.A., Rakhimova M.E., Salikhova M.F., Gadaev A.G. Risk narusheniya pochechnoi funktsii pri khronicheskoi serdechnoi nedostatochnosti. V sb.: Materialy III Mezhdunar. nauch.-prakt. konferentsii. Ulan-Ude: Vostochno-Sibirskii gosudarstvennyi universitet tekhnologii i upravleniya; 2015: 348–51. (in Russian). 8. Ezekowitz J.A., McAlister F.A., Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohortof 12 065 patients with new-onset heart failure. Circulation. 2003; 107(2): 223–5. 9. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575 –82.e3. 10. Lewis GD, Semigran MJ, Givertz MM, et al. Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron reple-tion effects on oxygen uptake in heart failure. Circ Heart Fail 2016;9:e000345. 11. Meshcheryakova L.M., Levina M.M., Tsybul'skaya A.A., Tret'yakov A.A., Suvorova N.N Osobennosti pokazatelei obmena zheleza (gepsidina, ferritina, HIF) pri smesh annykh anemiyakh. V sb. nauch. trudov: Tendentsii razvitiya nauki i obrazovaniya. Po materialam XXVII mezhdunar. nauch.-prakt. konferentsii. Samara, 30 iyunya 2017 g. Samara: L-Zhurnal; 2017. Chast' 1. (in Russian). 12. Nemeth E., Preza G.C., Jung C.L., Kaplan J., Waring A.J., Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-functionstudy. Blood. 2006; 107(1): 328–33. DOI: 10.1182/blood-2005-05-2049. 13. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J. S. et al. Rekomendatsii ESK po diagnostike i lecheniyu ostroi i khronicheskoi serdechnoi nedostatochnosti 2016. Ros. kardiol. zhurn. 2017; 1(141): 7–81. (in Russian). 14. Rukavitsyn O.A. Anemiya khronicheskikh zabolevanii: otdel'nye aspekty patogeneza i puti korrektsii. Onkogematologiya. 2016; 11(1): 37–46. (in Russian). 15. Sharova E.K., Babaeva L.A., Padaryan S.S., Soseliya N.N., Lukina O.I., Mil'to A.S. Khronicheskaya serdechnaya nedostatochnost': rekomendatsii i real'naya klinicheskaya praktika. Ratsion. farmakoterapiya v kardiologii. 2016; 12(6): 631–7. (in Russian). 16. Shcherbinina S.P., Levina A.A., Lisovskaya I.L., Attaullakhanov F.I. Deistvie ekzogennykh antioksidantov na antiokislitel'nyi status eritrotsitov i uroven' gepsidina v krovi bol'nykh s narusheniyami regulyatsii metabolizma zheleza. Biomed. khimiya. 2013; 6: 710–8. (in Russian). 17. Silverberg DS, Wexler D, Schwartz D. Is Correction of iron deficiency a New addition to the treatment of the heart failure? Int J Mol Sci. 2015;16:14056 –14074 . 18. Solomakhina N.I., Nakhodnova E.S., Ershov V.I. Anemiya pri khronicheskoi serdechnoi nedostatochnosti: rol' gepsidina kak universal'nogo regulyatora metabolizma zheleza. Zhurn. Serdech. Nedostatochnost'. 2014; 85(4): 254–60. (in Russian). 19. Stuklov N.I. Defitsit zheleza i anemiya u bol'nykh khronicheskoi serdechnoi nedostatochnost'yu. Ratsion. farmakoterapiya v kardiologii. 2017; 13(5): 651–60. (in Russian). 20. Vadhan-Raj S, Abonour R, Goldman JW, et al. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol 2017;10:73. 21. Zarudskii A.A., Shkileva I.Yu., Shelyakina E.V., Perutskii D.N., Perutskaya E.A. Izmenenie urovnya gemoglobina u bol'nykh s sistolicheskoi khronicheskoi serdechnoi nedostatochnost'yu. Zhurn. nauch. statei “Zdorov'e i obrazovanie v XXI veke”. 2018; 20(1): 165–9. (in Russian).
Gadayev, A.G.; Turakulov, R.I.; Kurbonov, A.K.; and Rakhimova, M.E.
"Role of Hepcidin and Pro-Inflammatory Cytokines in Chronic Heart Failure in Combination with Anemia,"
Central Asian Journal of Medicine: Vol. 2019
, Article 11.
Available at: https://uzjournals.edu.uz/tma/vol2019/iss3/11